

Board Composition Update – Succession Plan

Leadership Transition Plan Positions Rhythm for Next Phase of Growth

- ✓ **Mr Gavin Fox-Smith to assume the role of Chairman of the Board at 2025 AGM; and**
- ✓ **Mr Otto Buttula to retire and step down as a Director, effective 2025 AGM.**

Melbourne, Australia, 23 June 2025: Rhythm Biosciences Ltd ('RHY', the 'Company' or the 'Group') (ASX:RHY), a transformative, predictive cancer diagnostics technology company, is pleased to announce an important leadership transition aligned with the Company's long-term succession strategy.

Rhythm is a Company focussed on supporting an individual's ability to manage their health through cancer risk assessment, disease detection and therapy management. New methods for early disease detection are in demand as most cancers, particularly bowel cancer, are detected outside the recommended screening programs. Furthermore, early detection of disease generally leads to better outcomes.

As part of the Company's planned evolution and due to recent health matters, Non-Executive Chairman, Mr. Otto Buttula, has advised of his intention to not only retire as Chair, but to also step down as a Director, effective at the 2025 AGM.

Joining the Board post the Company's ASX listing, Mr. Buttula has led the Company through its most recent transformative milestones, including proteomic platform expansion into other cancers and the rebuilding of the ColoSTAT[®] kit programme into a more useable commercial product. He also oversaw the diversification into genetic testing, via the acquisition of Genetype[™] and first commercial sales.

The Company is also delighted to announce that Mr. Gavin Fox-Smith, a current Non-Executive Director, will assume the role of Chairman of the Board upon Mr Buttula's retirement at the 2025 AGM. Mr. Fox-Smith joined the Board on 2 December 2024 as part of the Company's succession plan. Gavin is a highly experienced leader in Health Technology. He is Chair of ANDHealth and a Non-Executive Director of Omnigon, Bowel Cancer Australia, SAN Foundation and United Way Australia.

The Board is confident that Mr. Fox-Smith's expertise will drive continued strategic execution and unlock further value for shareholders.

Mr. Gavin Fox-Smith stated:

"It is an honour to be appointed Chairman elect of Rhythm Biosciences, and I look forward to working closely with the Board, Management and entire Rhythm Team as we build on our recent momentum and continue to position the Company for sustainable growth."

Mr. Buttula commented:

"I have confidence in the Company's strategic direction and leadership team. The foundations we've laid over the past eighteen months has positioned Rhythm for long-term success. From resolving major legacy challenges to expanding our diagnostic product footprint through a key acquisition and ongoing partnership discussions, the progress has been remarkable. I am particularly proud of our team's resilience and the collective belief in the transformative value Rhythm brings to diagnostics. A new growth cycle is clearly underway, and the future is bright."

Key achievements over the past 18 months include:

- *Restructuring and rebuilding legacy ColoSTAT® product issues into a more manageable and sustainable commercial framework;*
- *Acquisition of Genetype™, enhancing our product offering and bringing first commercial revenues to the Group;*
- *Re-establishment of discussions with distributor and laboratory partners; and*
- *Board enhancement, with Mr. Fox-Smith bringing deep international med-tech expertise, particularly in diagnostics, and bowel cancer detection.*

I believe Rhythm is well-positioned to deliver innovative diagnostic solutions that improve both patient care and the health system in general. This leadership transition marks the beginning of an exciting new chapter, driven by a clear strategy, a committed team and ongoing shareholder support. As a major and committed shareholder, I look forward to the Company rebuilding value for all its stakeholders beginning in the period ahead as well as post my retirement."

- ENDS -

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information contact us via investors@rhythmbio.com.

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and X.

About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer is curable.

The ColoSTAT® Test-Kit is Rhythm Bioscience's simple blood-based test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood of CRC. The test is an alternative for individuals who are unable or unwilling to participate in current screening programs. It is being updated to meet relevant regulatory standards.

The ColoSTAT® Test-Kit is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

About geneType[™]

geneType[™] is a sophisticated genetic risk assessment testing platform that combines clinical, family history and genetic data to provide comprehensive risk assessments for various diseases. The platform leverages polygenic risk scores and clinical risk factors to generate personalized health insights, helping individuals and healthcare providers make more informed medical decisions. The technology allows for risk assessment across multiple conditions including breast cancer, cardiovascular disease, diabetes, colorectal cancer, prostate cancer and melanoma. The tests are delivered through healthcare providers and genetic counsellors, ensuring appropriate clinical oversight and support for patients receiving their results. The platform's multi-disease assessment capabilities and clinical utility position it well to capture growing demand in the preventative healthcare and precision medicine markets. For more information, please visit www.genetype.com.